An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to
patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys
180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during
treatment and for 24 weeks of follow-up.